A panel of four methylated genes (i.e., RASSF1A, WIF1, DAPK1, RARβ2) in combination with the EBV DNA test increase the sensitivity for NPC detection at an early stage (sensitivity = 0.96, specificity = 0.65, AUC = 0.83).84 The genome-wide DNA methylation profiling study revealed a methylation gene panel (i.e., WIF1, UCHL1, RASSF1A, CCNA1, TP73, SFRP1) as a prognostic biomarker for OS and DFS, which was also associated with the efficacy of concurrent chemotherapy in NPC.85 The gene discussed is UCHL1; the disease is nasopharyngeal carcinoma.